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Abstract. The discovery of extracellular vesicles (EVs) has 
revised the interpretation of intercellular communication. It is 
now well established that EVs play a significant role in coagula-
tion, inflammation, cancer and stem cell renewal and expansion. 
Their release presents an intriguing, transporting/trafficking 
network of biologically active molecules, which are able to 
reach and modulate the function/behavior of the target cells 
in a variety of ways. Moreover, the presence of EVs in various 
body fluids points to their potential for use as biomarkers and 
prognostic indicators in the surveillance/monitoring of a variety 
of diseases. Although vast knowledge on the subject of EVs has 
accumulated over the years, there are still fundamental issues 
associated with the correct approach for their isolation. This 
review comprises the knowledge on EV isolation techniques 
that are currently available. The aim of this reveiw was to make 
both experienced researchers and newcomers to the field aware 
that different types of EVs require unique isolation approaches. 
The realization of this ‘uniqueness’ is the first step in the right 
direction for the complete assessment of EVs.
Contents
1. Introduction
2. Concept of EV isolation
3. Cell culture medium
4. Body fluids
5. Storage and isolation conditions
6. Isolation
7. Polymeric precipitation
8. Biological activities of EVs and associated challenges
9. Conclusion
1. Introduction
Intercellular communication in a multicellular organism is 
essential for its proper functionality. Traditionally, soluble factors 
released by different types of cells were considered to serve 
such a role in a localized environment (1). With the emergence 
and discovery of small membrane sacs, later termed as extra-
cellular vesicles (EVs), that are released by various cell types, 
the concept of ‘cell-to-cell talk’ has been re-evaluated (2,3). It 
is now widely accepted that EVs have a substantial contribu-
tion to intercellular communication by shuttling bioactive 
molecules (transmembrane receptors, mRNAs, miRNAs and 
signaling molecules) that are able to modulate the extracellular 
environment (4-9). The term EV implies to all shed membrane 
vesicles, which can be further classified on the basis of their size, 
origin and their cargo (10). In general, however, EVs have been 
divided into two groups, exosomes and microvesicles (5,10,11). 
Exosomes are formed through invagination into endosomes to 
form multivesicular bodies (MVBs) and are thought to be some-
what unique in their protein and lipid composition (10). Due to 
their endosomal origin, exosomes contain membrane transport 
and fusion proteins (GTPases, Annexins and flotillin), tetraspan-
nins (CD9, CD63, CD81 and CD82), heat shock proteins (Hsc70 
and Hsp90), proteins involved in multivesicular body biogenesis 
(Alix and TSG101), as well as lipid-related proteins and phos-
pholipases (10,12,13), although other markers have also been 
associated with them (14). On the other hand, microvesicles are 
particles shed from the plasma membrane following stimula-
tion and are often a hallmark of cell apoptosis (15-17). Upon 
cell activation, as a result of stimuli, such as shear stress or 
cytokine/endotoxin release, the cytosolic calcium concentration 
increases, leading to the activation of a number of enzymes 
(calpains, gelsolins, scramblases and kinases) (16). This, in turn, 
leads to the inhibition of enzymes, such as translocases and 
phosphatases, resulting in cytoskeletal reorganization, the loss 
of membrane asymmetry and membrane blebbing, which causes 
microvesicle formation and release (16,18). Microvesicles have 
a rich phospholipid bilayer consisting of phosphatidyl serine on 
the outer leaflet and their membrane proteins reflect those of the 
cell they originate from (15,17,18).
2. Concept of EV isolation
The concept of EV isolation begins with the nature of the sample 
itself. First of all, one has to realize that different samples present 
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unique obstacles when it comes to EV isolation, which is greatly 
related to the origin of the EV. Thus, with respect to the source, 
EVs can be divided into two groups: i) those isolated from cell 
culture media, and ii) those isolated from body fluids (plasma, 
urine, spinal fluid, saliva, etc.).
3. Cell culture medium
When isolating EVs from conditioned cell culture media 
one has to consider the presence of an additional, ‘artificial’ 
EV source, namely fetal bovine serum (FBS) or any other 
supplement for that matter, which is routinely added to cell 
cultures (19,20). Our results obtained by nanoparticle tracking 
analysis (NTA) showed freshly prepared cell culture medium 
supplemented with FBS to have a substantial particle popula-
tion (mostly <100 nm in size) already present before the actual 
use (Fig. 1). This observation alone clearly demonstrates that the 
downstream EV isolation from conditioned cell culture media 
carries along the risk of obtaining, apart from proper EVs, also 
those from FBS, which obviously, obscures the final results. 
This observation is in accordance with observations of other 
groups, which have also shown FBS to contain vesicles that 
may be later isolated along the actual EV (19-21). To counter 
that problem, many groups apply filters to remove EVs from the 
media/FBS or use a long ultracentrifugation step. In an elegant 
study, Lötvall et al showed that the removal of FBS-originated 
EVs is critical for further downstream experiments, since 
these vesicles are capable of inducing effects similar to those 
of EVs isolated from the actual cell line culture media (21). 
Thus, it has been proposed that a 16 h-ultracentrifugation step 
at 100,000 x g or greater for FBS is absolutely obligatory for 
a complete FBS vesicle depletion, since shorter centrifugation 
steps are insufficient (19,21). An alternative may be the use of 
an exosome-free FBS, which is already commercially avail-
able, but is still rather expensive. Some also postulate the use of 
bovine serum albumin (BSA) instead of the standard FBS (20).
Another major issue involving EV isolation from condi-
tioned cell culture media regards the culture medium itself. 
Our NTA results revealed that even a newly opened cell culture 
medium contains a trace of particles that resemble EVs size-
wise (Fig. 1). The presence of these background particles itself 
puts tremendous strain on the integrity of the final EV isolation 
results. Similar results were obtained by Jeppesen et al, who 
compared two different cell culture media and showed that 
one type had more particle background than the other (19). 
Moreover, the storage temperature also seems to have an effect 
on the occurrence of the particles in a cell culture medium. A 
cell culture medium stored at room temperature showed more 
background particles than the one stored at 4˚C as observed by 
NTA, which was even more apparent with time passage (own 
data). It has been suggested that in such cases, ultracentrifuga-
tion for an extended period of time (16 h or longer) is necessary 
for the removal of particle background from the cell culture 
media (19).
There seems to be a strong demand for establishing a 
uniform protocol for EV isolation, particularly for EVs which 
are being isolated from cell culture media; however, this may 
not be so simple. Studies have shown that different cell lines 
generate unique EVs, suggesting that they should be consid-
ered individually with respect to the isolation approach. In 
their study, Jeppesen et al showed that the optimal isolation 
conditions for EVs obtained from embryonic kidney HEK293 
and bladder carcinoma FL3 cells differed from each other (19). 
Their study indicated that the optimal vesicle-to-protein yield 
for HEK293 cells was obtained at 67,000 x g, while that for 
FL3 cells was at 100,000 x g. Furthermore, it was demonstrated 
that specific g-force/k-factor usage during differential centrifu-
gation greatly influences the purity and yield of exosomes (19).
4. Body fluids
EV isolation from body fluids seems to be even more complex. 
Although the problem of the FBS vesicle presence obviously 
does not apply in this case, there are other factors (lipopro-
teins, DNA, RNA, protein aggregates and microbes) that need 
to be addressed for proper isolation (22-26). The majority of 
the available data concerns the overall EV population isolated 
from blood samples; however, there are attempts to ‘select 
out’ from that EV pool a certain type of EV depending on its 
origin (i.e., platelet, epithelial, leukocyte and tumor). Again, 
a careful approach needs to be undertaken for the isolation 
of the ‘wanted’ EV fraction(s). For example, if the isolation 
of leukocyte-origin EV is desired, the sample needs to be 
depleted of platelets. For that to be accomplished, platelets 
need to be centrifuged at a certain speed and under appropriate 
conditions (discussed in further detail below) to avoid platelet 
activation and, consequently, the generation of EVs of platelet 
origin (27,28). It has to be kept in mind that a blood sample (or 
any other body fluid sample for that matter) is a source of many 
types of EVs. Realizing the complexity of such samples puts 
another perspective on the EV fraction isolation approaches.
5. Storage and isolation conditions
There are no strictly defined conditions for storing/isolating 
EVs. One exception, however, are platelet-derived EVs, 
where firm guidelines for their proper acquisition have been 
laid down by the Vascular Biology group of the Scientific 
and Standardization Committee of the International Society 
Figure 1. Size distribution of particles obtained by nanoparticle tracking anal-
ysis (NTA) from cell culture medium sample supplemented with fetal bovine 
serum (FBS) and from freshly opened cell culture medium.
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on Thrombosis and Hemostasis over a decade ago (27-29). 
Although some basic framework has been established for other 
EVs, many groups have still independently developed their own 
storage/isolation protocols that are suitable to their individual 
laboratory settings (30). There is a general understanding that 
freshly acquired and processed samples guarantee the best EV 
yield; however, that is, for the most part, not possible (30,31).
Body fluid samples (blood, serum, plasma, urine and 
tumor ascites) are collected/stored in a number of ways. For 
example, there are studies demonstrating that blood samples 
collected on different anticoagulants, when processed further 
downstream, exhibit different EV yields (27,28). It has been 
shown that platelet and endothelial EV counts were substan-
tially lower in blood samples collected in citrate or EDTA than 
in the ones collected in protease inhibitors, either hirudin and 
soybean trypsin inhibitor or heparin (27-29,32). Some groups 
follow strict protocols and process their blood samples within 
1 h after collection (33). Others believe that a fasting period 
(of up to 12 h) prior to the sample collection is necessary for 
proper EV acquisition (27,28,34). On the other hand, others 
have indicated that storing blood samples, or any other body 
fluid samples for that matter, at 4˚C for up to 5 days does not 
affect the final EV yield (20). Observations have also been 
made that the EV diameter significantly decreases with the 
duration of the storage period (e.g., within 2 days) and with 
the increasing temperature during storage (from 4-37˚C) (35). 
Freezing and thawing cycles are also critical. Most groups 
are in agreement that multiple freezing-thawing cycles of a 
sample affect EV characteristics/concentration, although some 
suggest that repeating these cycles for up to 10 times has no 
influence on the size and composition of EVs to any significant 
degree (29-32,35). Moreover, the thawing conditions alone 
seem to play a crucial role in EV recovery. It has been observed 
that EV samples thawed on ice showed a lower EV recovery 
compared to the ones thawed at room temperature or 37˚C (36). 
To resolve this issue, aliquots of once obtained EV stocks are 
stored at -70 to -80˚C until use for up to a year, which then 
undergo only one freezing/thawing cycle (20,34). Zhou et al 
reported that the storage of EVs isolated from urine at -20˚C 
resulted in a major loss of EVs, while storage at -80˚C had no 
effect on the EV recovery (37).
In our opinion, the general rule for storage and isolation 
conditions should be ‘the sooner, the better’. The starting 
sample should be handled rapidly after collection, avoiding 
extensive waiting periods between further processing stages 
(i.e., centrifugation steps). In blood/plasma samples, all 
the necessary precautions (i.e., processing temperature, 
upright sample position for transport, no agitation) should 
be undertaken to avoid platelet activation, and thus potential 
platelet-derived EV generation. Moreover, once isolated, EV 
aliquots should be prepared, and they should undergo only one 
freezing/thawing cycle at an appropriate temperature to ensure 
optimal EV recovery.
6. Isolation
There are basically three major methodologies used for EV 
purification/isolation that serve as the backbone for potential 
method variations: i) differential centrifugation/ultracentrifu-
gation with/without a sucrose gradient/cushion; ii) adsorption 
to magnetic/non-magnetic microbeads; and iii) size exclusion 
chromatography.
Differential centrifugation/ultracentrifugation. This is 
probably the most commonly used method for EV isola-
tion/purification (20,30,38). As with other methods, there are 
variations depending on the laboratory setting; however, for 
the most part, the protocols follow the scheme that was put 
forward in the study by Raposo et al, who purified exosomes 
from the conditioned culture media of transformed human 
B cell lines (38). The protocol involves a number of sequential 
centrifugation steps at different centrifugal forces (g) whose 
purpose is to remove unwanted components from the actual 
exosomes. The first three steps of the protocol are designed 
to remove intact cells, dead cells or cell debris using three 
different centrifugal forces, that is 300 x g for 10 min, 2,000 x g 
for 10 min and 10,000 x g for 30 min, respectively. After each 
centrifugation, the supernatant is transferred into a new test 
tube while the generated pellets are being discarded. After 
the 10,000 x g spin, the supernatant is then subjected to a final 
ultracentrifugation at 100,000 x g for 70 min. The outcome 
of this step is an exosome pellet that can be used for further 
studies. It should be also noted that all the centrifugation steps 
are being carried out at 4˚C. The basic scheme for EV isolation 
is presented in Fig. 2.
Although the protocol presented in the study by 
Raposo et al (38) served as the backbone for others, it focused 
only on the purification of exosomes, a portion of the EV 
population with a size of <100 nm, and their isolation from 
conditioned cell culture media. With the discovery of EVs 
being present in all types of body fluids, there is an increasing 
need to adopt the protocol for appropriate samples with the 
incorporation of a step(s) enabling the isolation of EVs with 
a larger size (>100 nm). The EVs that can be obtained from a 
body fluid sample are divided into four distinct EV populations: 
exosomes, microvesicles, apoptotic bodies and microsomes (19). 
Exosomes (40-100 nm), the most extensively studied EV 
population, are usually isolated by centrifugation at 100,000-
200,000 x g (20,39), whereas microvesicles (100-1,000 nm) 
are isolated by centrifugation at 10,000-20,000 x g (30,40). 
Apoptotic bodies (50-5,000 nm) are obtained at a g-force 
of approximately 2,000 x g (19), whereas microsomes are 
80-120 nm in size and their isolation/identification needs to be 
confirmed by additional means (19,41,42). For the isolation of 
EVs from plasma, lymph fluid, urine, bronchiolar lavage fluid 
and tumor ascites, Théry et al proposed diluting the samples 
with an equal volume of PBS before further processing due to 
the viscosity of the respective fluids (20). Moreover, due to the 
complexity of the viscous fluid samples the time and centrifu-
gation speeds have been increased/adapted to obtain the 
appropriate EV populations. The major difference compared 
to the protocol presented in the study by Raposo et al (38) was 
made at the beginning of the modified protocol. Here, after 
the initial centrifugation step at 300 x g, another additional 
centrifugation at 2,000-3,000 x g for up to 30 min is performed, 
followed by the 12,000-15,000 x g step for up to 1 h. The purpose 
of the first step is to deplete the sample of cells/cellular debris. 
The second step enables the acquiring of apoptotic bodies, 
whereas the third one eliminates platelets/platelet EVs (plasma 
samples) and/or isolates microvesicles. Some groups at this 
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point check whether platelets/platelet EV have been removed 
from the centrifuged samples by anti-CD41, -CD61 mono-
clonal antibody staining and flow cytometry analysis (40). Only 
platelet-free plasma (PFP) and platelet EV-free plasma samples 
undergo further processing. It should be noted that, although 
some groups recommend centrifugation at 4˚C at all times, that 
should not be the case when dealing with plasma samples. The 
processing of these samples at this temperature leads to platelet 
activation, which in turn causes the generation of platelet EVs 
that may become difficult to remove downstream.
A variation of the EV isolation method by centrifugation 
that has been adopted by some groups includes an additional 
sucrose gradient/cushion step (43-45). Some argue that during 
EV isolation by centrifugation, aggregates of large proteins and/
or proteins that were non-specifically associated with EVs are 
also being sedimented (20,45). A sucrose gradient (20-60%)/
Figure 2. Differential centrifugation scheme, including a sucrose, iodixanol gradient/cushion step.
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cushion (30% sucrose) step incorporated into the centrifuga-
tion protocol supposedly eliminates this contamination, and 
the resulting EV population seems to be of a greater purity. 
The diluted (with PBS) EV suspension obtained by the protocol 
discussed above is gently loaded onto the Tris/sucrose/D2O 
solution containing tube and ultracentrifuged for a period of 
time (75 min up to overnight at 75,000 x g or greater) (20,44-
47). Following centrifugation, the EV fractions are collected 
based on their density, that ranges between 1.13-1.19 g/ml, 
diluted with PBS and centrifuged again for 30 min-2.5 h, at 
100,000 x g (20,44-47). Although the incorporation of the 
density gradient step into the EV isolation protocol has been 
designed to purify and isolate specific EV fractions, it has been 
recently reported that certain high-density lipoproteins (HDLs) 
can also be isolated using this method (48). An alternative to 
these problems may be the OptiPrep velocity gradient. In this 
method, 5-40% iodixanol gradient is used instead of sucrose, 
showing, reportedly, an improved separation of EVs from viral 
particles and small apoptotic bodies (47). Moreover, unlike 
sucrose, iodixanol is capable of forming iso-osmotic solutions 
at all densities, thus better preserving the size of the vesicles in 
the gradient (46).
Immunoaffinity isolation. Another method used for EV isola-
tion involves microbeads, usually magnetic, that are coated 
with an antibody that recognizes certain markers present on 
the EV surface. This technology can be used for EV isolation 
from either cell culture media or body fluids. After mixing the 
EV sample with the antibody-coated microbeads, a magnetic 
force is applied (i.e., to a column, microplate) which retains 
the EV-covered microbeads, while the rest of the sample is 
discarded (www.systembio.com/exosomes). Next, the micro-
beads with attached EV are eluted using appropriate buffers 
and used for further analysis. The advantage of this isolation 
method is its ability to select a specific EV population based 
on a marker expression regardless of its size. Many groups put 
in a lot of effort into selecting an EV fraction (i.e., exosomes 
and microvesicles) based on EV size, but not on the surface 
marker profile. Although this approach may result in obtaining 
valuable information on such EV fractions, it limits, however, 
the overall scope on the impact that the whole EV population, 
regardless of size, may exert on the surroundings. This is 
particularly evident in an in vivo setting where different types 
of cells may generate EVs of different sizes, but still carry the 
same surface marker (10). Another important advantage is the 
ability of coupling this method with other methods (i.e., flow 
cytometry, western blotting and ‘real-time’ PCR) to charac-
terize even further the already selected/specific EV fraction. 
At the same time, however, it needs to be pointed out that the 
beads, due to their physical binding surface area, can only bind 
a certain number of EVs, which, in turn, can lead to a substan-
tial population of EVs being still left out from the sample or lost 
during the purification process.
An alternative to magnetic microbeads are surfactant-free 
latex beads typically made of polystyrene (49), which are 
stabilized against aggregation by covalently linked charge 
groups (sulfate, carboxyl, amidine, carboxyl/sulfate, alde-
hyde/sulfate, chloromethyl and aldehyde/amidine) and have 
~95% of their surface available for passive adsorption of 
proteins (www.Invitrogen.com). They can be either hydrophobic 
or hydrophilic and can covalently bind EVs regardless of their 
size or surface marker composition. Due to this feature, the 
bound EVs can be further characterized by, for example, flow 
cytometry using multi-antibody staining, thus providing valu-
able information on the EVs. Although this method can lead to 
the acquisition of informative data on EVs, their elution from the 
beads is difficult. This is a major disadvantage to this method, 
since the bound EVs cannot be used in downstream experiments.
Size exclusion chromatography. This method is usually 
coupled with a low-speed centrifugation step that allows the 
removal of larger objects from the sample (cells, cellular 
debris, organelles, etc.) that is followed by a filtration step (0.8 
and 0.2 µm pore size filter) to pre-concentrate the EVs. The 
filtered EV sample is then subjected to size exclusion chroma-
tography (usually gel filtration column) where small volume 
fractions (1 ml) of the filtrate are collected and ultracentrifuged 
(100,000 x g, 1 h and longer) to pellet down the EVs (50-52). 
The principal behind this technique is that particles in a 
sample, depending on their size, will move through the filtra-
tion column at different rates. Thus, larger particles will elute 
more rapidly, while the smaller ones more slowly, due to their 
ability to penetrate the stationary phase (gel) of the column. 
In theory, the obtained eluted fraction at a certain time should 
contain a population of particles of the same particle size. The 
pelleted EVs are resuspended in PBS and used in downstream 
assays.
Although this method is generally established as one of the 
methods for EV isolation, it poses some concerns that need 
to be addressed. Forcing EV passage through filters used to 
pre-concentrate the sample may lead to EV deformation and 
eventual rapture into smaller particles (30). To avoid this, it has 
been suggested that size exclusion chromatography should be 
performed by gravity or with the application of the smallest 
possible force (23,30). Moreover, the selection of the appro-
priate gel type is crucial to the recovery of EVs, rather than 
proteins or lipoproteins. Additionally, the short isolation time 
and relatively low cost are also beneficial.
7. Polymeric precipitation
Although polymeric precipitation methods do not fall under the 
isolation method classification proposed above, it is worthwhile 
to mention them as an interesting and promising alternative. 
The concept behind this method is the formation of a mesh-
like polymeric web that captures EVs of a certain size, usually 
between 60-180 nm, which are later pelleted at low centrifugal 
speeds. It can be used to obtain EVs from both cell culture 
medium and/or body fluid samples. What is very appealing 
about this EV isolation method is the fact that it is relatively 
quick, enables high EV recoveries and does not require 
laborious ultracentrifugation (53). A previous study showed 
the superiority of this method over others; however, it only 
assessed the RNA yield and protein purity/quantity (54); thus, 
its possible application in the overall EV recovery still needs 
to be addressed. Others have raised a concern regarding the 
contaminants, such as lipoproteins, that may be isolated along 
with the actual EVs (30). Moreover, since polymeric precipita-
tion isolates EVs of 60-180 nm in size, it cannot be used for the 
assessment of larger EVs present in a sample.
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8. Biological activities of EVs and associated challenges
It is rather difficult to evaluate how the different isolation 
protocols affect the potential biological activities of EVs. 
The main reason for this is that the majority of available data 
concerns EVs isolated by a single method, and this mostly 
involves differential centrifugation/ultracentrifugation. At 
the same time, studies focusing on the comparison of the 
biological effects of EVs isolated by more than one protocol 
simply are unavailable, at least to the best of our knowledge. 
Most groups choose one isolation protocol through which 
EVs are obtained and their effect is then evaluated depending 
on the experimental design. For instance, exosomes isolated 
from red blood cells by ultracentrifugation are able to induce 
the release of pro-inflammatory cytokine in monocytes (55). 
Another study demonstrated that density-gradient isolated 
glioblastoma-derived EVs modified the phenotype of mono-
cytic cells (56). It has also been shown that RNA transferred 
by macrophage-derived microvesicles isolated by ultracen-
trifugation is biologically active and induces macrophage 
differentiation (57). Although there are attempts to compare 
two or more EV isolation methods, the results are limited to 
the correlation of EV physical properties (e.g., number, size 
distribution, phenotype, protein and/or RNA expression), and 
do not show the biological effects. For example, in a study on 
EVs present in blood and urine, it was suggested that polymeric 
precipitation yielded the highest EV concentration, although 
CD133 and CD63 protein expression in these EVs was difficult 
to interpret compared to EVs obtained by other methods (58). 
What makes the assessment of EV biological activities even 
more difficult is that there is no single isolation protocol to refer 
to as the ‘golden standard’ guaranteeing not just the complete 
recovery of EVs (all the fractions), but also the recovery of 
EVs that retain their native form/shape and function. Thus, it is 
simply unknown as to whether the obtained EVs, using either 
one of the protocols discussed above, comprise the original 
EVs released by the parent cells. Due to these discrepancies, 
additional simultaneous studies on the effects of different isola-
tion methods are warranted for the proper evaluation of EV 
biological activities.
9. Conclusion
The past decade has witnessed an extensive research in the EV 
field. As we learn more about EVs and their role under normal 
and/or pathological conditions, there is an increasing tempta-
tion of trying to use that knowledge in the treatment of certain 
diseases. Although elevated numbers of EVs or EVs bearing 
certain proteins, RNAs, miRNAs, etc. have been tagged as 
diagnostic and prognostic markers in a number of diseases, 
there still seems to be a question pending as to the validity 
of this information. The answer to this question begins with 
the establishment of firm EV isolation protocol(s) that would 
enable the assessment of the full spectrum of EVs present in a 
sample instantaneously. Available isolation protocols only in 
part meet this goal, as they tend to focus on the selection of a 
certain type(s) of EV, whether based on their size, density or 
marker expression. The outcomes of these approaches produce 
either inadequate EV numbers/concentration or contaminated 
EV population(s)/fraction(s), whose usefulness in downstream 
tests may be questionable. The isolation methods presented in 
this review comprise the current knowledge on the topic, shed-
ding a light on the complexity of the EV ‘world’.
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